Clinical trials: Gefitinib, completed
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Lung Cancer
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
- Trial name
- NCT00238628
- Testing
- Bexarotene, Iressa
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Pancreatic Cancer
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
The primary objective of the trial is to identify the dose of gemcitabine given as a 2-hour intravenous (iv) infusion that can be administered in combination with ZD1839 250 mg once daily and a standard course (45 Grays [Gy]) of…
- Trial name
- NCT00234416
- Testing
- Gefitinib, Gemcitabine
- Where
- 2 sites in Spain
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Lung Cancer, Breast Cancer
Iressa Follow-up Trial
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).
- Trial name
- NCT00357734
- Testing
- Gefitinib
- Where
- 7 sites in Germany
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Stage IV Non-small Cell Lung Cancer
Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth…
- Trial name
- NCT03595644
- Testing
- SBRT+TKI, TKI
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Tongji Hospital
Lung Cancer
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
the primary objective is to characterise the impact of gefitinib on the Response Evaluation Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ; confirmed complete response(CR) or partial response…
- Trial name
- ICARUS (NCT01530334)
- Testing
- Gefitinib 250mg
- Where
- 24 sites in Italy
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Lung Cancer
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005806
- Testing
- carboplatin, gefitinib, paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
This is a multi-center, open-label, randomized, Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) and to evaluate the efficacy in terms of progression free survival (PFS) of Tepotinib when used in combination with…
- Trial name
- NCT01982955
- Testing
- Tepotinib, Gefitinib, Pemetrexed
- Where
- 44 sites in China, Italy and 5 more
- Volunteers
- 88 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Calcitriol may help tumor cells develop into normal cells.
- Trial name
- NCT00084708
- Testing
- calcitriol, dexamethasone, gefitinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Roswell Park Cancer Institute
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Lung Cancer Stage III, EGFR Activating Mutation
Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma
Objective: To investigate the failure patterns, efficacy and safety of thoracic radiotherapy combined with EGFR-TKI in stage III unresectable non-small cell lung cancer harboring EGFR-sensitive mutations.
- Trial name
- NCT07857694
- Testing
- Thoracic radiotherapy, EGFR-TKI
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Laibin People's Hospital
Colorectal Cancer
IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
The primary objective of the Phase I part of the study is to determine the recommended dose of capecitabine to be administered in combination with ZD1839 250 mg orally once daily in subjects with advanced or metastatic colorectal…
- Trial name
- NCT00242788
- Testing
- Gefitinib and capecitabine
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00025142
- Testing
- FOLFOX regimen, fluorouracil, gefitinib
- Where
- United States
- Sponsor
- Stanford University
Non-Small-Cell Lung Cancer
Combination of Chemotherapy and Gefitinib as First-line Treatment
The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS and OS of patients with NSCLC. However, outcome of the combination therapy are similar to those reported in several trials of single-agent…
- Trial name
- NCT02148380
- Testing
- pemetrexed plus carboplatin, gefitinib
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Baohui Han
Neoplasms, Unknown Primary
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with…
- Trial name
- NCT00193596
- Testing
- Etoposide, Gemcitabine, Irinotecan
- Where
- 31 sites in United States
- Volunteers
- 198 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Metastatic Prostate Cancer
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer
- Trial name
- NCT00239291
- Testing
- Gefitinib, radiotherapy
- Where
- Finland
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms
Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma
Non-small cell lung cancer (NSCLC) is the most frequent neoplasm worldwide and also represents the main cause of cancer death. However, it represents the main cause of death by cancer.
- Trial name
- NCT02805530
- Testing
- First line systemic treatment, Radical treatment, radiation therapy
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Pneumonic-type Adenocarcinoma (P-ADC), Lung Adenocarcinoma With Bronchiolo-alveolar Feature
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtype in the 2004 WHO…
- Trial name
- NCT00198380
- Testing
- Gefitinib
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa
The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions…
- Trial name
- EPIDAURE (NCT01448187)
- Where
- 29 sites in France
- Volunteers
- 361 people
- Sponsor
- AstraZeneca